WHO, Eli Lilly warn against fake versions of popular weight loss, diabetes drugs
Written By : Ruchika Sharma
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2024-06-22 11:16 GMT | Update On 2024-06-22 11:16 GMT
Advertisement
Geneva: The World Health Organization (WHO) and pharmaceutical company Eli Lilly and Co. are cautioning the public about fake versions of popular weight-loss and diabetes medications. WHO reported on Thursday that it has received numerous reports of fake semaglutide, which is the active ingredient in Novo Nordisk's Wegovy and Ozempic, across all global regions since 2022.
Lilly said in an open letter that it was "deeply concerned" about growing online sales and social media posts involving phony or compounded versions of tirzepatide, the active ingredient behind its drugs Mounjaro and Zepbound.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.